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Abstract 
Tumor necrosis factor-α inhibitors may induce various cutaneous side effects including 
eczematous-like lesions. The management of such side effects can be challenging. Herein, we 
report a case of a 55-year-old man who had a flare-up and subsequent improvement of 
atopic dermatitis during treatment of severe psoriasis with adalimumab. 
© 2013 S. Karger AG, Basel 
Introduction 
While the efficacy of tumor necrosis factor (TNF)-α inhibitors for the treatment of 
chronic plaque psoriasis has been well established, their therapeutic benefits in atopic 
dermatitis (AD) has remained controversial [1–3]. In addition, some reports, including large 
case series, have even described the induction of eczematous and AD-like lesions by TNF-α 
inhibitors and have advised against their use in patients with an atopic constitution and 
eczema [4–7]. We here report a case on the management of psoriasis associated with AD 
using adalimumab. 
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Case Report 
A 55-year-old man with long-standing severe recalcitrant plaque psoriasis was treated 
with an 80-mg loading dose of adalimumab, and thereafter 40 mg every other week. The 
patient had an atopic constitution with a personal history of allergic rhinoconjunctivitis and 
asthma, and he was concomitantly suffering from slightly active AD in his armpits. There was 
no family history of atopic disorders. After 3 months of therapy with adalimumab, a marked 
improvement of his psoriasis (PASI 75 response) was observed (fig. 1a, b). However, 
together with this improvement, new eczematous lesions had begun to flare up on his neck, 
armpits, and hands (fig. 2a–d). Localization of the eczematous lesions was characteristic of a 
flare-up of AD. His atopic constitution was further substantiated by positive skin prick tests 
to house dust mites, cats, grass and birch pollen as well as by raised total IgE levels (253 
kU/l; normal value <100 kU/l). Therapy with adalimumab was continued due to a beneficial 
response of the psoriatic lesions, while the eczematous lesions were temporarily treated 
with topical corticosteroids (mometasone ointment for 3 weeks daily and twice weekly 
thereafter). The topical corticosteroids were discontinued after 6 weeks. Together with 
further amelioration of the psoriatic lesions (fig. 1c), a marked improvement of his AD was 
subsequently also observed during the following 5 months (fig. 2e–h).  
Discussion 
Psoriasis and AD belong to the most frequent chronic inflammatory skin diseases. The 
clinical and pathophysiological features between psoriasis and AD differ substantially and an 
inverse association of both diseases has also been reported [8–11]. Although the simultane-
ous occurrence of both diseases appears to be rare, few patients, as described in this case, 
may concomitantly have psoriasis and AD. Indeed, genomic studies indicate that psoriasis 
and AD may have a couple of shared genes which regulate the proliferation and differentia-
tion of epidermal cells and modulate general cutaneous inflammatory mechanisms [12, 13]. 
In addition, both diseases are characterized by T-cell-dominated dermal infiltrates and a 
good responsiveness to T-cell-directed agents. Recent studies have further delineated the 
phenotype of the infiltrating T cells in psoriasis and AD [10, 11]. While psoriasis is mainly 
mediated by Th1 and Th17 cells, AD is driven by Th2 and Th22 cells. Furthermore, Th1 cells 
producing cytokines like IFN-γ and TNF-α are also thought to contribute to the chronic 
phase of AD.  
The recognition of TNF-α as a key regulator of inflammation in general and its possible 
involvement in the development of chronic AD lesions also led to the use of TNF-α inhibitors 
in AD [14]. While some reports have failed to show substantial beneficial responses, others 
have demonstrated successful treatment of recalcitrant AD by TNF-α inhibitors [1–3]. 
Although a flare-up of AD was initially noted in our patient, therapy with adalimumab could 
be continued and ultimately lead to amelioration of both psoriasis and AD. To our 
knowledge, this is the first case reporting the successful management of psoriasis associated 
with AD using adalimumab. 
As noted in our case, some reports, including large case series, have also described the 
induction of eczematous and AD-like lesions by TNF-α inhibitors [4–7]. These eczematous 
eruptions were either newly developed or flared up in patients with an atopic constitution. 
Most of these AD-like reactions were of moderate intensity and were managed well with 
topical corticosteroid or calcineurin inhibitors [5, 6], although severe cases necessitating 
hospitalization or discontinuation of treatment have also been reported [7].  
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In conclusion, physicians should be aware that eczematous lesions may flare up during 
the therapy with TNF-α inhibitors, especially in patients with an atopic constitution. 
However, these flares can often be managed without withdrawing the TNF-α inhibitor and 
by using topical corticosteroids. Furthermore, based on some similarities in the inflammato-
ry process of both chronic AD and psoriasis, as well as the encouraging therapy results in at 
least some cases, TNF-α inhibitors may even be beneficial for patients with severe AD at a 
chronic stage. 
Disclosure Statement 
Nikhil Yawalkar has served as a consultant to Abbott.  
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Fig. 1. Marked improvement of psoriasis during treatment with adalimumab. a Before treatment. b After 
3 months. c After 8 months. 
 
 
 
Fig. 2. a–d Flare-up of AD at month 3. e–h Subsequent amelioration of AD after application of topical 
corticosteroids for 6 weeks and continuing treatment with adalimumab with a few remaining lesions after 
8 months. 
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